Among the most critical molecular targets in cancer therapy are Cyclin-Dependent Kinase 2 (CDK2), Epidermal Growth Factor Receptor (EGFR), and Tubulin, each of which plays a pivotal role in tumor progression and development of drug resistance. This evidence concerns the gene CDK2 and cancer.